Heidrun Irschik-Hadjieff takes over as CEO of Sanofi in Germany
13.09.2023 11:50
Heidrun Irschik-Hadjieff will head Sanofi in Germany in the future. She will take over as CEO on November 1, 2023, in addition to her previous duties as head of the Vaccines business unit. The company's supervisory board passed a corresponding resolution at its meeting on September 7th.
Irschik-Hadjieff succeeds Fabrizio Guidi, who chaired the management of Sanofi in Germany for the past five years and at the same time headed the General Medicines business unit in the Germany-Switzerland-Austria multi-country organization. Guidi is moving to the company headquarters in Paris and taking on new tasks there. His successor at General Medicines will be Anita Ouwerkerk on October 1st, who joined Sanofi from Novartis on September 1st.
Brendan O'Callaghan, CEO and Chairman of the Supervisory Board of Sanofi in Germany: “The Supervisory Board is pleased to appoint Heidrun Irschik-Hadjieff, an experienced manager from our own ranks who is characterized by comprehensive strategic thinking and action - far beyond the expertise at the company vaccines. In this respect, your order is more than logical! I would like to thank Fabrizio for his strong leadership of the German organization in recent years, which he not only set up in a completely different cultural way, but also got it through the Corona pandemic well. I would like to thank Fabrizio very much for this and look forward to working together at group level.”
Before joining Sanofi in April 2022, Heidrun Irschik-Hadjieff was managing director at Takeda Pharma Vertriebs GmbH & Co. KG in Berlin and also spokesperson for Takeda GmbH in Konstanz. She has many years of expertise in a wide range of indication areas, from rare diseases and multiple sclerosis to ophthalmology and the field of vaccines. Born in Vienna and mother of two daughters, she began her career in the pharmaceutical industry after graduating with a master's degree in commercial science from the Vienna University of Economics and Business and an MBA from Webster University. Before Takeda, she worked at CIBA Vision and Novartis in Vienna and Prague, among others.
With the change at the top of Sanofi in Germany on November 1, 2023, the management board will then consist of three women and two men
Heidrun Irschik-Hadjieff, Chairwoman of the Board and Managing Director of Vaccines
Oliver Coenenberg, Managing Director of Human Resources and Organization and Labor Director
Marcus Lueger, Managing Director Finance
Anne Reuschenbach, Managing Director of Pharmaceutical Production & Manufacturing
Dr. Marion Zerlin, Managing Director Research & Development